Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
Author(s) -
Linus Angenendt,
Christoph Röllig,
Pau Montesinos,
David MartínezCuadrón,
Eva Barragán,
Raimundo García,
Carmen Botella,
Pilar Martı́nez,
Farhad Ravandi,
Tapan M. Kadia,
Hagop M. Kantarjian,
Jorge E. Cortés,
Gunnar Juliusson,
Vladimir Lazarević,
Martin Höglund,
Sören Lehmann,
Christian Récher,
Arnaud Pigneux,
Sarah Bertoli,
Pierre-Yves Dumas,
Hervé Dombret,
Claude Preudhomme,
JeanBaptiste Micol,
Christine Terré,
Zdeněk Ráčil,
Jan Novák,
Pavel Žák,
Andrew H. Wei,
Ing Soo Tiong,
Meaghan Wall,
Elihu H. Estey,
Carole Shaw,
Rita Exeler,
Lisa Wagenführ,
Friedrich Stölzel,
Christian Thiede,
Matthias Stelljes,
Georg Lenz,
Jan-Henrik Mikesch,
Hubert Serve,
Gerhard Ehninger,
Wolfgang E. Berdel,
Michael Krämer,
Utz Krug,
Christoph Schliemann
Publication year - 2019
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.00416
Subject(s) - medicine , npm1 , myeloid leukemia , oncology , pooled analysis , myeloid , cancer research , karyotype , genetics , gene , chromosome , biology , meta analysis
Nucleophosmin 1 ( NPM1 ) mutations are associated with a favorable prognosis in acute myeloid leukemia (AML) when an internal tandem duplication (ITD) in the fms-related tyrosine kinase 3 gene ( FLT3 ) is absent ( FLT3 -ITD neg ) or present with a low allelic ratio ( FLT3 -ITD low ). The 2017 European LeukemiaNet guidelines assume this is true regardless of accompanying cytogenetic abnormalities. We investigated the validity of this assumption.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom